HANGZHOU, China, July 18, 2022 /PRNewswire/ BRONCUS COMPLETED SURGERIES ON THE FIRST GROUP OF PATIENTS USING ITS InterVapor®, THE THERMAL VAPOR TREATMENT SYSTEM, AFTER APPROVED FOR MARKETING IN CHINA
HANGZHOU, China, July 18, 2022 /PRNewswire/ Broncus Medical (02216.HK) has completed surgeries on the first group of patients using its InterVapor(including InterVapor Generator and InterVapor Catheter, the "InterVapor"), after it was approved for marketing in China. This marked the official entry of InterVapor into the clinical commercialization phase in China and is expected to benefit patients with chronic obstructive pulmonary disease ("COPD"). The surgeries were completed by teams of professionals led by Professor Long Fa of the Department of Respiratory, Shenzhen Hospital, University of Chinese Academy of Science; and Professor Ouyang Haifeng of the Department of Respiratory and Critical Care Medicine, Chest Hospital, Xi'an International Medical Center Hospital, respectively. The Company's self-developed InterVapor was granted approval by the National Medical Products Administration of China (the "NMPA") in March 2022. This is the first NMPA